Johns Hopkins spinout Personal Genome Diagnostics Inc. is looking to raise up to $3.5 million in new funding in support of its push to commercialize its cancer diagnostic technology.
Canton-based PGDx has already raised $2.7 million in the new round of debt and security financing, according to documents filed with the U.S. Securities and Exchange Commission. CEO Megan Bailey said the new funding comes from existing investors. The company is previously backed by about $147 million and its recent backers include Innovatus Capital Partners, Bristol-Myers Squibb, Cowin Capital, Helsinn Investment Fund, Inova Health System, Windham Venture Partners, as well as Maryland Venture Partners, New Enterprise Associates and Camden Partners.